HPB Unit, Department of General Surgery, Hospital Universitari de Tarragona Joan XXIII, 43005 Tarragona, Spain.
Departament of Medicine and Surgery, Universitat Rovira i Virgili, 43204 Reus, Spain.
Int J Mol Sci. 2023 Jan 6;24(2):1127. doi: 10.3390/ijms24021127.
There is a clear association between the molecular profile of colorectal cancer liver metastases (CRCLM) and the degree to which aggressive progression of the disease impacts patient survival. However, much of our knowledge of the molecular behaviour of colorectal cancer cells comes from experimental studies with, as yet, limited application in clinical practice. In this article, we review the current advances in the understanding of the molecular behaviour of CRCLM and present possible future therapeutic applications. This review focuses on three important steps in CRCLM development, progression and treatment: (1) the dissemination of malignant cells from primary tumours and the seeding to metastatic sites; (2) the response to modern regimens of chemotherapy; and (3) the possibility of predicting early progression and recurrence patterns by molecular analysis in liquid biopsy.
结直肠癌肝转移(CRCLM)的分子特征与疾病侵袭性进展对患者生存的影响程度之间存在明确的关联。然而,我们对结直肠癌细胞分子行为的了解主要来自于实验研究,这些研究在临床实践中的应用还很有限。在本文中,我们回顾了结直肠癌肝转移分子行为的最新研究进展,并提出了可能的未来治疗应用。本综述重点关注 CRCLM 发展、进展和治疗的三个重要步骤:(1)恶性细胞从原发肿瘤的扩散和转移部位的定植;(2)对现代化疗方案的反应;(3)通过液体活检中的分子分析预测早期进展和复发模式的可能性。